Ipilimumab + Temozolomide in Metastatic Melanoma

NCT01119508 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Temozolomide

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]